Kezar Life Sciences Nears Potential Regulatory Inflection Point

Kezar Life Sciences nears a critical FDA meeting to resolve the development path for zetomipzomib in autoimmune hepatitis, aiming to avoid a major trial delay.

A pivotal quarter lies ahead for Kezar Life Sciences, with the potential for a significant regulatory breakthrough concerning its lead drug candidate, zetomipzomib. The company is working to resolve a lengthy disagreement with the U.S. Food and Drug Administration (FDA) over the development path for treating autoimmune hepatitis (AIH). Successful negotiations could prevent a feared two-year delay in the clinical program.

Financial Position and Strategic Review

As of September 30, 2025, Kezar reported holding approximately $90.2 million in cash, cash equivalents, and marketable securities. The market will gain further insight into the company's financial health next month, March 2026, when it releases its fourth-quarter and full-year 2025 earnings. These results will clarify the impact of recent cost-saving initiatives and the evolution of its cash reserves since the fall.

In parallel, management has been conducting a review of strategic alternatives since October 2025, aimed at maximizing shareholder value. Initial steps in this process have already included implementing cost-reduction measures and a workforce reduction to focus resources on core development projects.

A Path Forward with the FDA

The focal point of current developments is a scheduled "Type C" meeting with the FDA, set for the first quarter of 2026. The objective is to align on a pathway for a global, randomized Phase 2b clinical trial. This represents a constructive shift following an impasse last October, when the agency canceled a planned meeting and imposed additional requirements.

At that time, regulators mandated a standalone pharmacokinetic study in patients with severe liver impairment before any new AIH trials could commence. The FDA also requested a 48-hour patient monitoring period within a clinical research setting—a condition Kezar argued would severely hinder patient recruitment. In response, the company has submitted additional safety data and an updated risk mitigation plan to address these specific concerns.

The upcoming discussions are therefore critical. A favorable outcome would chart a clear course for zetomipzomib's advancement in AIH, moving past previous obstacles and toward late-stage clinical evaluation.